5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P. and related parties, including Peter Kolchinsky and Rajeev M. Shah, sold 116,046 shares of Vor Biopharma Inc. NASDAQ:VOR common stock on October 20 and 21, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales, totaling $3,433,992, occurred at prices ranging from $28.11 to $30.12. According to InvestingPro data, VOR stock has shown significant volatility, with a remarkable 106.55% price return over the past six months, despite the current market cap of $181.29M.
Specifically, on October 20, the entities sold 70,366 shares at an average price of $29.63 and 6,553 shares at an average price of $30.12. Additionally, 13,817 shares were sold at an average price of $29.63 and 1,287 shares at an average price of $30.12. On October 21, they sold 25,027 shares at an average price of $28.11.
Following these transactions, RA Capital Healthcare Fund, L.P. directly holds 1,401,226 shares and RA Capital Nexus Fund, L.P. holds no shares. InvestingPro analysis reveals that Vor Biopharma maintains a strong liquidity position, holding more cash than debt on its balance sheet, though the company is currently experiencing rapid cash burn. Discover more insights about VOR’s financial health with InvestingPro’s comprehensive research report, available along with 10+ additional ProTips.
RA Capital Management, L.P. serves as the investment manager for RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P. Peter Kolchinsky and Rajeev Shah are managing members of RA Capital Management GP, LLC, the general partner of the Adviser. All parties have disclaimed beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest.
Sarah Reed, General Counsel of the Adviser, is a member of Vor Biopharma’s board of directors.
In other recent news, Vor Biopharma announced that its collaborator RemeGen’s Phase 3 study of telitacicept in primary Sjögren’s disease met both its primary and secondary endpoints. The 48-week trial conducted in China showed significant improvements in disease activity, with 71.8% of patients receiving telitacicept 160mg achieving a meaningful reduction in disease activity at 24 weeks, compared to 19.3% of placebo patients. These promising results have led Baird to upgrade Vor Biopharma’s stock rating from Neutral to Outperform, citing the potential of telitacicept. Baird has also significantly raised its price target for Vor Biopharma to $64.00 from $20.00. Additionally, Vor Biopharma is set to present these findings at the ACR Convergence 2025 conference in Chicago. The presentation will be a late-breaking poster showcasing the results from the multicenter, randomized, double-blind, placebo-controlled trial. Vor Bio will also host a webcast to discuss the 48-week Phase 3 clinical data for telitacicept in primary Sjögren’s disease. This webcast will include insights from Vor Bio management and Ronald van Vollenhoven, a Professor of Rheumatology at Amsterdam University Medical Center.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.